ClinicalTrials.gg
CompletedNCT01131000Updated May 26, 2010

Efficacy, Safety, and Pharmacokinetics of Intravenous Ibuprofen in Adult Febrile Patients

A Phase 3 interventional study of Ibuprofen and Ibuprofen in Fever, sponsored by Cumberland Pharmaceuticals. Completed at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-05-26.

Sponsored by Cumberland Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 19 studies testing ibuprofen in Fever — none open to participants now, none under way, none of them phase 3. Ibuprofen · Fever.

Enrollment
8th of 18
123 · median 119
Started
2002
the only one that year
Phase 3
6 of 19
none open now
Registered
8th of 19
by date
Lead sponsor
5 of 19
Cumberland Pharmaceuticals

Among the 19 studies testing ibuprofen in Fever, this one is the 8th largest by enrollment of the 18 interventional ones that give a count, is the only one that started in 2002, is one of 6 in phase 3, and was the 8th registered.

Fever

438 studies on the registry are indexed under Fever; 55 are open to participants now.

Browse Fever studies →

Open to participants now

None of the 19 studies testing ibuprofen in Fever is open now. The open studies under Fever, anywhere →

About ibuprofen

Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 38 Fever studies recruiting now, 18 (47%) set no upper age limit and 14 (37%) stop at 75 or younger; 22 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing ibuprofen in Fever as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of intravenous ibuprofen on reducing fever at 4 hours.

Read the detailed description

The primary objective of this study is to evaluate the efficacy of a single 400 mg dose of intravenous ibuprofen on reducing fever greater than or equal to 101.0ºF (38.3ºC), as compared with the efficacy of parallel placebo treatment.

03

Conditions studied

  • Fever

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be hospitalized
  2. Have new (not chronic, within last 7 days) onset of fever, documented by temperature greater than or equal to 101.0ºF (38.3ºC)
  3. Have adequate intravenous access
  4. Have the ability to understand the requirements of the study, be willing to provide written (as evidenced by signature on an informed consent document approved by an Institutional Review Board), and agree to abide by the study restrictions and to return for the required assessments

Exclusion criteria

Exclusion Criteria:

  1. Be less than 18 years of age
  2. Have received antipyretic drug therapy (e.g., aspirin, other NSAIDs, or acetaminophen) within 4 hours before dosing
  3. Have any history of allergy or to any component of IVIb, NSAIDs (including aspirin), or COX-2 inhibitors
  4. Be pregnant or nursing
  5. Have a history of severe head trauma that required current hospitalization, intracranial surgery, or stroke within the previous 30 days, or any history of intracerebral arteriovenous malformation, cerebral aneurysm, or central nervous system mass lesions
  6. Weigh less than 40 kg
  7. Have a history of congenital bleeding diatheses (e.g., hemophilia) or any active bleeding, or have underlying dysfunction, including (but not limited to) idiopathic thrombocytopenic purpura, disseminated intravascular coagulation, or congenital platelet dysfunction
  8. Have gastrointestinal bleeding that has required medical intervention within the previous 6 weeks (unless definitive surgery has been performed)
  9. Have a platelet count less than 30,000/mm3
  10. Be receiving full dose anticoagulation therapy
  11. Have fever secondary to blood or drug reaction
  12. Have an expected life span of less than 14 days because of imminent withdrawal of life support or severity of illness
  13. Be receiving treatment with (Patients who are expected to receive corticosteroids during the Treatment Period or through Hour 120 of the Post-treatment Period are not eligible.)
  14. Have neurogenic fever
  15. Be on dialysis, have oliguria or creatinine greater than 3.0 mg/dL, or be receiving nephrotoxic drugs
  16. Have had major surgery within the past 12 hours, unless adequate hemostasis has been achieved
  17. Have received another drug within the past 30 days
  18. Become afebrile (temperature below 101.0ºF [38.3ºC]) before dosing and not redevelop fever entry criteria during this hospitalization
  19. Be otherwise unsuitable for the study, in the opinion of the Investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    Ibuprofen

    Drug: Ibuprofen

  • Placebo comparator
    Saline

    Normal Saline

    Other: Normal Saline

Interventions

  • Intravenous ibuprofen, 100 mg, Single-dose

  • Intravenous ibuprofen, 200mg, single dose

  • Intravenous ibuprofen, 400 mg, Single-dose

  • OtherNormal Saline

    Normal Saline, 100 ml, Single-dose

    Also known as: 0.9 % NaCL; 0.9 % Sodium Chloride

06

What researchers measure

Primary outcomes

  1. Percent of patients with fever reduction to less than 101.0 degree fahrenheit following a single dose of intravenous ibuprofen.

    Time frame: 4 hours

07

Study locations

11 sites
  • Orlando Regional Medical Center
    Orlando, Florida 32806, United States
  • Barnes Jewish Hospital
    St. Louis, Missouri 63110, United States
  • Moses H. Cone Memorial Hospital
    Greensboro, North Carolina 27401, United States
  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina 27157, United States
  • Methodist Healthcare - University Hospital
    Memphis, Tennessee 38104, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37203, United States
  • Skyline Medical Center
    Nashville, Tennessee 37207, United States
  • Ben Taub General Hospital
    Houston, Texas 77030, United States
  • Newcastle Mater Misericordiae Hospital
    New Lambton, New South Wales 2305, Australia
  • Flinders Medical Centre
    Adelaide, South Australia, Australia
  • Mahidol University Siriraj Hospital
    Bangkok, 10700, Thailand
08

References and documents

Publications

  • Morris PE, Promes JT, Guntupalli KK, Wright PE, Arons MM. A multi-center, randomized, double-blind, parallel, placebo-controlled trial to evaluate the efficacy, safety, and pharmacokinetics of intravenous ibuprofen for the treatment of fever in critically ill and non-critically ill adults. Crit Care. 2010;14(3):R125. doi: 10.1186/cc9089. Epub 2010 Jun 30. PubMed 20591173 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2002, a primary completion of Aug 2005 and a completion of Aug 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2010
First posted
May 26, 2010
Start
Jun 2002
Primary completionActual
Aug 2005
CompletionActual
Aug 2005
Last update
May 26, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01131000
First posted
May 26, 2010
Start date
Jun 2002
Primary completion
Aug 2005
Completion
Aug 2005
Last update
May 26, 2010

Study contacts

Gordon Bernard, M.D.
study chair · Cumberland Pharmaceuticals, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ibuprofen

Start the discussion